Substance P increased oxidative stress in prostate cancer cells by reducing key antioxidant enzymes, while blocking its NK1R receptor with aprepitant reversed these effects.
Aprepitant reverses SP effectsNK1R blockade restored antioxidant enzyme levels and reduced oxidative stress caused by Substance P in prostate cancer cells
What the researchers found
Substance P/NK1R signaling increased ROS and decreased both the expression and activity of glutaredoxin and thioredoxin in PC3 and LNCaP prostate cancer cells. Aprepitant (NK1R antagonist) reversed all of these effects.
Why it matters
Substance P is elevated in many cancers. Understanding how this neuropeptide disrupts cellular antioxidant defenses reveals a new mechanism of cancer promotion and identifies NK1R blockade as a potential therapeutic strategy for prostate cancer.
The numbers in context
The study measured changes in both expression and activity levels of glutaredoxin and thioredoxin proteins in response to SP/NK1R activation.
How the study worked
In vitro study using PC3 and LNCaP prostate cancer cell lines. Cells treated with Substance P and/or aprepitant (NK1R antagonist). Measured cell viability (resazurin assay), intracellular ROS levels, and glutaredoxin/thioredoxin expression (qRT-PCR) and activity (commercial kits).
Who was studied
Prostate cancer cell lines treated with Substance P
What this study cannot tell us
In vitro study using established cancer cell lines, which do not replicate the complexity of tumors in the body. Aprepitant concentrations used in cell culture may not match achievable clinical doses. No animal or human data. The specific contribution of this redox mechanism to overall cancer progression is unclear.
How to read the evidence
Preliminary evidence: in vitro cell line study demonstrating a specific mechanism. No animal or human data to confirm clinical relevance.
When this study was published
Published in 2024. Contributes to growing evidence on neuropeptide involvement in cancer biology.
The bigger picture
The nervous system and cancer are increasingly recognized as interconnected. Neuropeptides like Substance P can directly influence tumor biology. This study adds oxidative stress manipulation to the list of ways Substance P promotes cancer, and suggests that repurposing the anti-nausea drug aprepitant — already approved and well-tolerated — could have anti-cancer applications.
Questions still open
- Does aprepitant reduce prostate cancer growth in animal models through this oxidative stress mechanism?
- Are Substance P levels elevated in prostate cancer patients, and does this correlate with tumor aggressiveness?
- Could combining aprepitant with standard prostate cancer treatments enhance their effectiveness?
Common questions
What is Substance P and how does it affect cancer?
Could the anti-nausea drug aprepitant help fight cancer?
Read the original research
The effect of SP/NK1R on expression and activity of glutaredoxin and thioredoxin proteins in prostate cancer cells.
Naunyn-Schmiedeberg's archives of pharmacology, 397(8), 5875-5882
Citation
Zarei Shandiz, Sara; Assaran Darban, Reza; Javid, Hossein; Ghahremanloo, Atefeh; Hashemy, Seyed Isaac. (2024). The effect of SP/NK1R on expression and activity of glutaredoxin and thioredoxin proteins in prostate cancer cells.. Naunyn-Schmiedeberg's archives of pharmacology, 397(8), 5875-5882. https://doi.org/10.1007/s00210-024-02996-x